A self-inactivating γ-retroviral vector reduces manifestations of mucopolysaccharidosis i in mice

Molecular Therapy

Volumn 18, Issue 2, 2010, Pages 334-342

  Metcalf, Jason A ^a   Ma, Xiucui ^a   Linders, Bruce ^a   Wu, Susan ^a   Schambach, Axel ^b   Ohlemiller, Kevin K ^a   Kovacs, Attila ^a   Bigg, Mark ^a   He, Li ^a   Tollefsen, Douglas M ^a   Ponder, Katherine P ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; ALPHA 1 ANTITRYPSIN; CD40 LIGAND; DERMATAN SULFATE; GLYCOSAMINOGLYCAN; HEPARIN COFACTOR II; LEVO IDURONIDASE; PARVOVIRUS VECTOR; RETROVIRUS VECTOR; SCATTER FACTOR; SELF INACTIVATING GAMMA RETROVIRUS VECTOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA; AORTA DISEASE; ARTICLE; BONE DISEASE; CONTROLLED STUDY; DNA DETERMINATION; EAR DISEASE; EYE DISEASE; GENE EXPRESSION REGULATION; GENE THERAPY; HEARING; HURLER SYNDROME; IMMUNOBLOTTING; LONG TERMINAL REPEAT; MOUSE; NONHUMAN; PROMOTER REGION; PROTEIN EXPRESSION; RNA ANALYSIS; SIGNAL TRANSDUCTION; VIRAL GENE DELIVERY SYSTEM; VISION;

MUS;

EID: 76349105717     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2009.236     Document Type: Article

References (33)

1. Baehner, F, Schmiedeskamp, C, Krummenauer, F, Miebach, E, Bajbouj, M, Whybra, C, et al. (2005). Cumulative incidence rates of the mucopolysaccharidoses in Germany. J Inherit Metab Dis 28: 1011-1017.
2. Neufeld, EF and Muenzer, J (2001). The mucopolysaccharidoses. In: Scriver CR, Beaudet AL, Sly WS, Valle D (eds). Metabolic and Molecular Basis of Inherited Disease. McGraw Hill: New York, pp. 3421-3452.
3. Boelens, JJ, Rocha, V, Aldenhoven, M, Wynn, R, O'Meara, A, Michel, G, et al.; EUROCORD, Inborn error Working Party of EBMT and Duke University (2009). Risk factor analysis of outcomes after unrelated cord blood transplantation in patients with hurler syndrome. Biol Blood Marrow Transplant 15: 618-625.
4. Clarke, LA, Wraith, JE, Beck, M, Kolodny, EH, Pastores, GM, Muenzer, J, et al. (2009). Long-term effcacy and safety of laronidase in the treatment of mucopolysaccharidosis I. Pediatrics 123: 229-240.
5. Sifuentes, M, Doroshow, R, Hoft, R, Mason, G, Walot, I, Diament, M, et al. (2007). A follow-up study of MPS I patients treated with laronidase enzyme replacement therapy for 6 years. Mol Genet Metab 90: 171-180.
6. Ponder, KP and Haskins, ME (2007). Gene therapy for mucopolysaccharidosis. Expert Opin Biol Ther 7: 1333-1345.
7. Liu, Y, Xu, L, Hennig, AK, Kovacs, A, Fu, A, Chung, S, et al. (2005). Liver-directed neonatal gene therapy prevents cardiac, bone, ear, and eye disease in mucopolysaccharidosis I mice. Mol Ther 11: 35-47.
8. Ma, X, Tittiger, M, Knutsen, RH, Kovacs, A, Schaller, L, Mecham, RP, et al. (2008). Upregulation of elastase proteins results in aortic dilatation in mucopolysaccharidosis I mice. Mol Genet Metab 94: 298-304.
9. Kobayashi, H, Carbonaro, D, Pepper, K, Petersen, D, Ge, S, Jackson, H, et al. (2005). Neonatal gene therapy of MPS I mice by intravenous injection of a lentiviral vector. Mol Ther 11: 776-789.
10. Hartung, SD, Frandsen, JL, Pan, D, Koniar, BL, Graupman, P, Gunther, R, et al. (2004). Correction of metabolic, craniofacial, and neurologic abnormalities in MPS I mice treated at birth with adeno-associated virus vector transducing the human cc-L-iduronidase gene. Mol Ther 9: 866-875.
11. Ponder, KP, Wang, B, Wang, P, Ma, X, Herati, R, Wang, B, et al. (2006). Mucopolysaccharidosis I cats mount a cytotoxic T lymphocyte response after neonatal gene therapy that can be blocked with CTLA4-Ig. Mol Ther 14: 5-13.
12. Traas, AM, Wang, P, Ma, X, Tittiger, M, Schaller, L, O'donnell, P, et al. (2007). Correction of clinical manifestations of canine mucopolysaccharidosis I with neonatal retroviral vector gene therapy. Mol Ther 15: 1423-1431.
13. Herati, RS, Knox, VW, O'Donnell, P, D'Angelo, M, Haskins, ME and Ponder, KP (2008). Radiographic evaluation of bones and joints in mucopolysaccharidosis I and VII dogs after neonatal gene therapy. Mol Genet Metab 95: 142-151.
14. Di Domenico, C, Di Napoli, D, Gonzalez Y Reyero, E, Lombardo, A, Naldini, L and Di Natale, P (2006). Limited transgene immune response and long-term expression of human a-L-iduronidase in young adult mice with mucopolysaccharidosis type I by liver-directed gene therapy. Hum Gene Ther 17: 1112-1121.
15. Ma, X, Liu, Y, Tittiger, M, Hennig, A, Kovacs, A, Popelka, S, et al. (2007). Improvements in mucopolysaccharidosis I mice after adult retroviral vector-mediated gene therapy with immunomodulation. Mol Ther 15: 889-902.
16. Herati, RS, Ma, X, Tittiger, M, Ohlemiller, KK, Kovacs, A and Ponder, KP (2008). Improved retroviral vector design results in sustained expression after adult gene therapy in mucopolysaccharidosis I mice. J Gene Med 10: 972-982.
17. Aronovich, EL, Bell, JB, Khan, SA, Belur, LR, Gunther, R, Koniar, B, et al. (2009). Systemic correction of storage disease in MPS I NOD/SCID mice using the sleeping beauty transposon system. Mol Ther 17: 1136-1144.
18. Nair, V (2008). Retrovirus-induced oncogenesis and safety of retroviral vectors. Curr Opin Mol Ther 10: 431-438.
19. Kraunus, J, Schaumann, DH, Meyer, J, Modlich, U, Fehse, B, Brandenburg, G, et al. (2004). Self-inactivating retroviral vectors with improved RNA processing. Gene Ther 11: 1568-1578.
20. Schambach, A, Mueller, D, Galla, M, Verstegen, MM, Wagemaker, G, Loew, R, et al. (2006). Overcoming promoter competition in packaging cells improves production of self-inactivating retroviral vectors. Gene Ther 13: 1524-1533.
21. Schambach, A, Bohne, J, Baum, C, Hermann, FG, Egerer, L, von Laer, D, et al. (2006). Woodchuck hepatitis virus post-transcriptional regulatory element deleted from X protein and promoter sequences enhances retroviral vector titer and expression. Gene Ther 13: 641-645.
22. Zychlinski, D, Schambach, A, Modlich, U, Maetzig, T, Meyer, J, Grassman, E, et al. (2008). Physiological promoters reduce the genotoxic risk of integrating gene vectors. Mol Ther 16: 718-725.
23. Maruggi, G, Porcellini, S, Facchini, G, Perna, SK, Cattoglio, C, Sartori, D, et al. (2009). Transcriptional enhancers induce insertional gene deregulation independently from the vector type and design. Mol Ther 17: 851-856.
24. Randall, DR, Colobong, KE, Hemmelgarn, H, Sinclair, GB, Hetty, E, Thomas, A, et al. (2008). Heparin cofactor II-thrombin complex: a biomarker of MPS disease. Mol Genet Metab 94: 456-461.
25. Nemes, A, Timmermans, RG, Wilson, JH, Soliman, OI, Krenning, BJ, ten Cate, FJ, et al. (2008). The mild form of mucopolysaccharidosis type I (Scheie syndrome) is associated with increased ascending aortic stiffness. Heart Vessels 23: 108-111.
26. Tittiger, ME, Ma, X, Xu, L and Ponder K (2008). Neonatal intravenous injection of a y-retroviral vector has a low incidence of tumor induction in mice. Hum Gene Ther 11: 1217-1323.
27. Stoltzfus, LJ, Sosa-Pineda, B, Moskowitz, SM, Menon, KP, Dlott, B, Hooper, L, et al. (1992). Cloning and characterization of cDNA encoding canine a-L-iduronidase. mRNA defciency in mucopolysaccharidosis I dog. J Biol Chem 267: 6570-6575.
28. Ohmi, K, Greenberg, DS, Rajavel, KS, Ryazantsev, S, Li, HH and Neufeld, EF (2003). Activated microglia in cortex of mouse models of mucopolysaccharidoses I and IIIB. Proc Natl Acad Sci USA 100: 1902-1907.
29. Ohlemiller, KK, Vogler, CA, Roberts, M, Galvin, N and Sands, MS (2000). Retinal function is improved in a murine model of a lysosomal storage disease following bone marrow transplantation. Exp Eye Res 71: 469-481.
30. Hennig, AK, Ogilvie, JM, Ohlemiller, KK, Timmers, AM, Hauswirth, WW and Sands, MS (2004). AAV-mediated intravitreal gene therapy reduces lysosomal storage in the retinal pigmented epithelium and improves retinal function in adult MPS VII mice. Mol Ther 10: 106-116.
31. Ohlemiller, KK, Hennig, AK, Lett, JM, Heidbreder, AF and Sands, MS (2002). Inner ear pathology in the mucopolysaccharidosis VII mouse. Hear Res 169: 69-84.
32. Gao, C, Sands, MS, Haskins, ME and Ponder, KP (2000). Delivery of a retroviral vector expressing human p-glucuronidase to the liver and spleen decreases lysosomal storage in mucopolysaccharidosis VII mice. Mol Ther 2: 233-244.
33. Wang, B, O'Malley, TM, Xu, L, Vite, C, Wang, P, O'Donnell, PA, et al. (2006). Expression in blood cells may contribute to biochemical and pathological improvements after neonatal intravenous gene therapy for mucopolysaccharidosis VII in dogs. Mol Genet Metab 87: 8-21.